Related by context. All words. (Click for frequent words.) 71 cranial irradiation 67 thrombotic complications 66 colorectal liver metastases 66 differentiated thyroid 66 thyroid nodules 66 percutaneous biopsy 66 squamous cell lung cancer 65 metastatic lymph nodes 65 intraperitoneal chemotherapy 65 Adjuvant chemotherapy 65 PCNSL 65 axillary dissection 64 serous ovarian cancer 64 spontaneous regression 64 adjuvant therapies 64 BEXXAR Therapeutic Regimen 64 curative resection 64 liver metastasis 64 epithelial tumors 64 malignant pleural mesothelioma 64 radioimmunotherapy RIT 64 Hurthle cell 64 axillary node dissection 63 bronchogenic carcinoma 63 HIV HCV coinfected 63 GIST tumors 63 precursor lesions 63 Radiofrequency ablation 63 pediatric malignancies 63 cervical lymph nodes 63 thymic carcinoma 63 histologic subtype 63 pituitary adenomas 63 KRAS mutation 63 malignant growths 63 histological subtype 63 peritoneal carcinomatosis 63 debulking surgery 63 mutated K ras 63 chest radiographs 63 colorectal adenoma 63 carcinoid tumor 63 hamartomas 63 gastric cardia 63 histopathologic examination 63 leiomyomas 63 K ras mutations 63 prostate carcinoma 63 Sentinel node biopsy 63 bone scintigraphy 63 basal cell cancers 63 intravenous bisphosphonates 63 carotid artery blockage 63 nonmelanoma skin cancers 63 papillary renal cell carcinoma 63 GISTs 63 mucinous 63 thyroid carcinoma 63 colorectal adenocarcinoma 63 lung nodule 63 preoperative chemotherapy 62 carcinoid tumors 62 intraductal 62 radiochemotherapy 62 Adjuvant therapy 62 recurrent glioblastoma multiforme 62 breast carcinoma 62 lymph node dissection 62 angiographically 62 Surgical resection 62 subgroup analyzes 62 tumor excision 62 multimodality therapy 62 cranial radiation 62 prostate cancer CaP 62 urothelial cancer 62 rebleeding 62 catheter angiography 62 arteriography 62 conventional angiography 62 Radical prostatectomy 62 renal tumors 62 pancreatic adenocarcinoma 62 Chronic pancreatitis 62 locoregional recurrence 62 extrapleural pneumonectomy 62 carotid plaques 62 chemoprevention trials 62 clinicopathologic 62 stratifying patients 62 resected tumors 62 node metastases 62 mediastinal lymph nodes 62 surgically resectable 62 gastric adenocarcinoma 62 perfusion abnormalities 62 antiangiogenic therapy 62 Neoadjuvant chemotherapy 62 spinal metastases 62 KRAS status 62 allogeneic HSCT 62 metastatic uveal melanoma 62 ovarian malignancy 62 prognostically 62 immunocompetent 62 recurrent metastatic 62 pathologic examination 62 anti angiogenic agents 62 Squamous 62 postoperative radiotherapy 62 incidentalomas 62 endometrial hyperplasia 62 malignant neoplasm 61 esophagogastric junction 61 carcinoids 61 diagnostic modality 61 Heavy menstrual bleeding 61 biliary tract cancer 61 wedge resection 61 Basal cell 61 nonalcoholic steatohepatitis NASH 61 duplex ultrasonography 61 FDG PET 61 Tumor Response 61 clinicopathological 61 aerodigestive tract 61 metaplasia 61 sentinel lymph node biopsy 61 axillary lymph node 61 revascularization procedures 61 adenomatous polyps 61 #F FDG PET 61 grade gliomas 61 malignant neoplasms 61 histological subtypes 61 intensive statin therapy 61 sentinel nodes 61 pelvic lymphadenectomy 61 unresectable tumors 61 LVRS 61 axillary lymph nodes 61 rtPA 61 metastatic neuroendocrine tumors 61 radioiodine therapy 61 skeletal metastases 61 perioperatively 61 colorectal neoplasms 61 follicular lymphoma FL 61 cytoreductive surgery 61 osteoporotic compression fractures 61 tumor histology 61 cytotoxic therapies 61 nonsmall cell lung cancer 61 β blockers 61 renal cell carcinomas 61 radiographic findings 61 frameless radiosurgery 61 etiologic factors 61 coinfected patients 61 endoscopic ultrasonography 61 Metastatic colorectal cancer 61 colorectal cancer liver metastases 61 osteosarcomas 61 nodal metastasis 61 hepatic lesions 61 Colon polyps 61 adjuvant radiotherapy 61 primary hyperparathyroidism 61 antiplatelet medications 61 LVNC 61 transrectal ultrasound guided 61 carcinoid 61 noncardiac 61 intracranial stenosis 61 surgical debulking 61 hepatic metastases 61 tamoxifen Nolvadex ® 61 histologies 61 severe exacerbations 61 invasive carcinoma 61 DVT PE 61 lymph node removal 61 superficial bladder cancer 61 Hepatocellular Carcinoma HCC 61 thromboembolic disease 61 relapsed SCLC 61 breast endometrial 61 HSCT 61 extracranial 61 carotid plaque 61 EUS FNA 61 SLNB 61 gastrointestinal stromal tumors GIST 60 unruptured aneurysm 60 familial clustering 60 lymphomas leukemias 60 ICD implantation 60 renal biopsy 60 Glioblastoma Multiforme GBM 60 Postoperative complications 60 serologic tests 60 thrombolytic agents 60 oral anticoagulation 60 hepatocellular carcinomas 60 esophageal gastric 60 operable breast cancer 60 haematologic 60 TRUS biopsy 60 melanoma lesions 60 hematopoietic cancers 60 tumoral 60 fibrinolytic therapy 60 extramedullary 60 resectable 60 concurrent chemoradiation 60 perioperative complications 60 coronary CTA 60 androgen ablation 60 gemcitabine carboplatin 60 Lymph node 60 FDG-PET/CT 60 intraperitoneal therapy 60 portal vein thrombosis 60 Randomized trials 60 thymoma 60 trastuzumab Herceptin ® 60 ADVEXIN therapy 60 prostate cancer metastases 60 neoadjuvant treatment 60 colon resection 60 seminomas 60 pulmonary metastases 60 LV dysfunction 60 indolent lymphomas 60 acetabular fractures 60 adrenalectomy 60 medically inoperable 60 transfusion syndrome 60 chemoembolization 60 malignant lesions 60 antithrombotic therapy 60 metastatic melanomas 60 scintigraphic 60 colonoscopic 60 distal colon 60 rFVIIa 60 peritoneal cancer 60 antimicrobial prophylaxis 60 riociguat 60 histopathologic findings 60 malignant lymphomas 60 acute STEMI 60 postoperative chemotherapy 60 locoregional 60 immunohistochemical 60 tumor subtype 60 underarm lymph nodes 60 neuroendocrine cancers 60 gastroesophageal junction 60 oesophageal adenocarcinoma 60 acute aortic dissection 60 troponins 60 polyp recurrence 60 ConclusionThis 60 thymectomy 60 paragangliomas 60 curative therapy 60 cisplatin chemotherapy 60 gadobutrol 60 Chronic lymphocytic leukemia 60 saline infusion 60 radiolabeled TM# 60 cystic lesions 60 DCIS lesions 60 neoadjuvant therapy 60 incomplete revascularization 60 UA NSTEMI 60 anthracycline chemotherapy 60 FDG PET imaging 60 postoperative AF 60 intracerebral haemorrhage 60 completely resected 60 monogenic 60 sarcomatoid 60 immunohistochemical analysis 60 ANCA associated 60 EGFR mutation positive 60 ZOLINZA 60 immunosuppressive regimen 60 intestinal metaplasia 60 enucleation 60 cytologic 60 renal carcinoma 60 axillary nodes 60 metastatic lesion 60 hepatectomy 60 chest radiography 60 chromosomal mutations 60 biliary strictures 60 histologically proven 60 adrenocortical cancer 60 neuroblastoma tumors 60 Alequel 60 GnRH agonists 60 percutaneous cryoablation 60 CTEPH 60 unstable angina UA 60 osteoporotic vertebral compression fractures 60 Surgical excision 60 BCR ABL mutations 60 urothelial carcinoma 59 hepatic arterial 59 preoperative MRI 59 refractory colorectal cancer 59 idiopathic pulmonary 59 molecular abnormalities 59 neoplastic lesions 59 cytological 59 ductal cancer 59 mitochondrial toxicity 59 prostate carcinomas 59 malignant prostate 59 coronary blockages 59 pilocytic astrocytomas 59 neoplasias 59 prognostic indicators 59 arthrography 59 plasminogen activators 59 antiplatelet drugs 59 ablative therapy 59 chemoradiation therapy 59 liver transplant recipients 59 invasive aspergillosis 59 adnexal mass 59 NMIBC 59 basal cell carcinoma BCC 59 pelvic radiotherapy 59 mutated KRAS gene 59 biochemical abnormalities 59 Leukemias 59 HIPEC 59 N. gonorrhoeae 59 nonmetastatic 59 precancerous condition 59 malignant lesion 59 metastatic lesions 59 pCR 59 squamous histology 59 Venous thromboembolism 59 postoperative complication 59 sputum specimens 59 postoperative infections 59 venous thromboembolic disease 59 histologic findings 59 dexrazoxane 59 follicular thyroid cancer 59 EoE 59 invasive lobular carcinoma 59 adjuvant radiation 59 obstructive coronary 59 hormone receptor status 59 cisplatin resistant 59 pulmonary toxicity 59 pathologic diagnosis 59 cediranib 59 cryptogenic 59 metachronous 59 advanced adenoma 59 ADPKD 59 subclinical disease 59 micrometastasis 59 colon tumors 59 hyperplastic polyps 59 GI bleeds 59 localized prostate 59 Gliadel Wafer 59 intestinal polyps 59 undergoing CABG 59 neuroendocrine carcinoma 59 metastatic gastric 59 anal lesions 59 core needle biopsies 59 aromatase inhibitors AIs 59 advanced adenomas 59 Hormonal therapy 59 radical nephrectomy 59 Platinol ® cisplatin 59 malignant polyps 59 VCUG 59 oncological outcomes 59 Zevalin consolidation 59 pleural mesothelioma 59 stage IIIA 59 GBMs 59 sonographic appearance 59 pharmacogenetic testing 59 lung resection 59 immune reconstitution syndrome 59 CIN3 59 candidemia 59 prostate cancer PCa 59 metastatic malignant melanoma 59 chemotherapeutic regimen 59 antireflux surgery 59 preoperative diagnosis 59 MGd 59 pulmonary metastasis 59 adverse cytogenetics 59 preoperative staging 59 reflux symptoms 59 mesotheliomas 59 abnormal cytology 59 pneumonectomy 59 cytoreduction 59 hypervascular 59 colonic polyps 59 lumbar disk herniation 59 poor metabolizers 59 bullous 59 perioperative morbidity 59 carotid artery stenting 59 malignant ascites 59 PROCHYMAL 59 supratentorial 59 chemotherapeutic regimens 59 hyperoxaluria 59 cervical carcinoma 59 nodal dissection 59 intracranial hemorrhage ICH 59 cardiac troponin 59 androgen deprivation 59 lung metastasis 59 bowel polyps 59 pulmonary nodules 59 mycosis fungoides 59 antiproliferative effects 59 prognostic biomarker 59 Metastatic breast cancer 59 EGFR tyrosine kinase inhibitors 59 comorbid disorders 59 Adenomas 59 antioxidant supplementation 59 relapsed MM 59 inhaled bronchodilators 59 invasive ductal breast cancer 59 antibiotic prophylaxis 59 fibrinolysis 59 urine cytology 59 HBeAg negative 59 percutaneous drainage 59 extracapsular extension 59 nephron sparing surgery 59 empiric treatment 59 chronic periodontitis 59 endometrial carcinoma 59 cutaneous melanoma 59 meningiomas 59 untreated celiac disease 59 trans retinoic acid 59 chlamydial infection 59 genomic biomarker 59 ovarian endometrial 59 pyridostigmine 59 adenomatous 59 TGFBR1 * 6A 59 Cytoxan 59 invasive ductal 59 pelvic lymph nodes 59 gastroduodenal 59 smoldering multiple myeloma 59 contralateral breast 59 neutropenic patients 59 transthyretin amyloidosis 59 prognostic markers 59 eculizumab therapy 59 Gleevec resistant 59 benign nodules 59 ovarian suppression 59 prognostic variables 59 EGFR blockers 59 Computed tomography 59 precancerous polyp 59 antiarrhythmic medications 59 antibiotic regimens 59 MGUS 59 carcinomatosis 59 paricalcitol 59 diagnostic angiography 59 glomerular filtration 58 osteoid 58 cytotoxic therapy 58 recurrent glioblastoma multiforme GBM 58 histological diagnosis 58 renal scarring 58 pancreatectomy 58 EBUS 58 fibroadenomas 58 ventricular remodeling 58 systolic dysfunction 58 seminoma 58 postoperative morbidity 58 penicillin allergy 58 malignant nodules 58 recurrent ischemic stroke 58 histologic examination 58 HER2 positive cancers 58 fibroadenoma 58 corticosteroid therapy 58 ß blockers 58 ASCUS 58 hypercoagulable 58 paroxysmal AF 58 cerebral microbleeds 58 Stereotactic radiosurgery 58 cerebral angiography 58 grade cervical intraepithelial 58 invasive candidiasis 58 gastrointestinal stromal tumor 58 tumor resection 58 RAS mutations 58 malignant lymphoma 58 microwave hyperthermia 58 hepatorenal syndrome 58 papillary thyroid carcinoma 58 bladder carcinoma 58 benign thyroid nodules 58 postoperative atrial fibrillation 58 advanced neoplasia 58 Mohs micrographic surgery 58 standard chemotherapy regimen 58 calculi 58 demonstrated antitumor activity 58 neoplasm 58 neurologic complications 58 alveolar rhabdomyosarcoma 58 radiation therapy SBRT 58 metastatic bladder 58 uterine fibroid 58 thoracoscopic lobectomy 58 underwent resection 58 pulmonary artery catheter 58 diagnose coronary artery 58 pseudoaneurysm 58 HoLEP 58 biliary stones 58 Mitomycin C 58 anaplastic 58 nonpharmacologic 58 cystoscopic 58 vesicoureteral reflux 58 immunohistochemical staining 58 Papillary 58 thromboembolic complications 58 noscapine 58 percutaneous interventions 58 spirometric 58 histologic diagnosis 58 beta carotene supplementation 58 oncologic outcomes 58 coronary intervention 58 intestinal biopsy 58 benign polyps 58 macrovascular events 58 selenium supplementation 58 lymphatic tissue 58 Doxil ® 58 mTOR inhibitors 58 microsatellite instability 58 prospectively enrolled 58 endobronchial 58 thrombocytopenic 58 perioperative mortality 58 CYP#D# gene 58 antiplatelet therapies 58 beta blocker therapy 58 stereotactic radiotherapy 58 micrometastases 58 VADT 58 methotrexate monotherapy 58 baseline LDH 58 intravesical therapy 58 chemo resistant 58 metaanalysis 58 transrectal ultrasound 58 myelofibrosis polycythemia vera 58 anticoagulant warfarin 58 vascular anomalies 58 renoprotective 58 lymphadenectomy 58 NCCN guidelines 58 autoimmune pancreatitis 58 heparin induced thrombocytopenia 58 lymph node metastases 58 sonographic evaluation 58 thiopurine 58 recurrent glioma 58 percutaneous coronary interventions 58 GBA mutations 58 de novo AML 58 neoplasms 58 IPAH 58 NSTE ACS 58 herpes simplex encephalitis 58 cellularity 58 recurrent venous thromboembolism 58 chemo immunotherapy 58 cancerdefine 58 gadolinium enhanced 58 antitumor effect 58 relapsed ALL 58 prognostic indicator 58 squamous 58 mesenteric 58 Carotid endarterectomy 58 p# biomarker 58 colorectal carcinoma 58 biologic plausibility 58 hyperacute 58 gefitinib Iressa 58 BRCA mutation carriers 58 chemoradiotherapy 58 anthracycline therapy 58 chemosensitivity 58 pheochromocytoma 58 empiric therapy 58 liver metastases 58 glycoprotein IIb IIIa inhibitors 58 sCJD 58 histologically confirmed 58 taxane therapy 58 lung nodules 58 somatic mutations 58 premalignant lesions 58 artery stenosis 58 esophagectomy 58 chemotherapy docetaxel 58 repigmentation 58 HER2 overexpression 58 curability 58 relapsing remitting MS RRMS 58 pre cancerous growths 58 node dissection 58 Glioblastoma multiforme 58 hereditary predisposition 58 pa tients 58 polypoid 58 nodal metastases 58 perfusion defects 58 differentiating squamous 58 pancreatic carcinoma 58 System IPSS 58 tumorigenicity 58 murine models 58 primary aldosteronism 58 thrombo embolic 58 nonmelanoma 58 ImmuKnow 58 atherosclerotic lesions 58 CP CPPS 58 Xelox 58 clinico pathological 58 breast cancer subtypes 58 atypical ductal hyperplasia 58 ductal adenocarcinoma 58 liver resection 58 Malignant glioma 58 neurologic deficits 58 fibrocystic 58 ischemic cardiomyopathy 58 infective endocarditis 58 silent ischemia 58 colorectal gastric 58 Prognostic factors 58 transesophageal echocardiography 58 hamartoma 58 pretransplant 58 multivariate analyzes 58 endometrial biopsy 58 Cystoscopy 58 transurethral resection 58 polypoid lesions 58 pelvic ultrasound 58 HGPIN 58 ACOSOG Z# 58 HIV tropism 58 Ceplene/IL-2 58 adenocarcinomas 58 deep venous thromboses 58 cervical lymph node 58 precancers 58 chromosomal aberrations 58 autologous transplants 58 visceral metastases 58 attain statistical significance 58 angiography CTA 58 proximal colon 58 neovascularisation 58 lung metastases 58 pelvic examinations 58 platelet reactivity 58 excisional biopsy 58 multicentric 58 immunosuppressive therapies 58 myxoma 58 F FDG PET 58 underwent coronary angiography 58 stage IIIb IV 58 KRAS mutations 58 axillary lymph node dissection 58 transcranial Doppler 58 epidural steroid injections 58 Sezary syndrome 58 extracolonic 58 gastric cancers 58 resections 58 sentinel node biopsy 58 dosimetric 58 OnDose TM 58 STEP BD 58 diagnosing coronary artery 58 FFR measurements 58 lung cancer NSCLC 57 renal cysts 57 gallium nitrate 57 radiotherapy RT 57 arterial calcification 57 Barrett esophagus BE 57 membranous nephropathy 57 malignant ovarian 57 precancer 57 CT perfusion 57 STEMIs 57 gastric carcinoma 57 pleural fluid 57 diabetic kidney 57 anticholinergic agents 57 GBM tumors 57 bullous pemphigoid 57 CYT# potent vascular disrupting 57 alkylating agents 57 submandibular gland 57 pulmonary dysfunction 57 adenoidectomy 57 carotid stenosis 57 Subgroup analyzes 57 Waldenstrom macroglobulinemia 57 abdominal ultrasounds 57 coronary stenosis 57 squamous carcinoma 57 somatoform disorders 57 tumor subtypes 57 familial pancreatic cancer 57 pharmacologic stress 57 lobular carcinomas 57 molecularly defined 57 antiangiogenic agent 57 Sentinel Lymph Node Biopsy 57 histologic subtypes 57 chest radiograph 57 non squamous histology 57 reinfarction 57 RE LY trial 57 latent celiac disease 57 idiopathic myelofibrosis 57 sonographic diagnosis 57 hepatocellular carcinoma liver 57 EBUS FNA 57 FDG uptake 57 urinary bladder cancer 57 melanocytic 57 RECIST Response Evaluation Criteria 57 ovarian carcinoma 57 non squamous NSCLC 57 pancreatic ductal adenocarcinoma 57 HNSCC 57 ABCB1 57 coagulation abnormalities 57 pre cancerous lesion 57 histopathologic 57 elevated LDH 57 recurrent DVT 57 AA Amyloidosis 57 recurrent NSCLC 57 orchitis 57 endoscopic retrograde cholangiopancreatography ERCGrant Parpan 57 diagnostic workup 57 prognostic marker 57 therapeutic regimens 57 localized renal 57 tipranavir ritonavir 57 Autoimmune hepatitis 57 retrospective cohort 57 T#I [002] 57 minimally symptomatic 57 sonographically guided 57 calcified plaques 57 bacterial prostatitis 57 RAS blockers 57 CT coronary angiography 57 anticlotting drugs 57 symptomatic VTE 57 bleomycin 57 Candida infection 57 bowel resection 57 TMEM density 57 biopsied tissue 57 FluCAM arm 57 antitumor efficacy 57 urolithiasis 57 cystectomy 57 efficacy evaluable 57 adjuvant cisplatin 57 tigecycline 57 hepatoma 57 S. maltophilia 57 lymphocytic 57 Meta analyzes 57 leukemias lymphomas 57 rt PA 57 oral anticoagulant therapy 57 hypertrophic scars 57 esophagogastric 57 radiofrequency ablation RFA 57 Cardiotoxicity 57 FDG PET scans 57 pT2 57 Seewaldt 57 Multivariate logistic regression 57 ALI ARDS 57 histological examination 57 neoadjuvant chemotherapy 57 pancreatic islet cell 57 impair fertility 57 Cardiopulmonary bypass 57 underlying pathophysiology 57 atherothrombotic disease 57 thrombi 57 cisplatin gemcitabine 57 anticonvulsant medications 57 cytogenetic abnormalities 57 clevidipine 57 infantile hemangiomas 57 antiangiogenic agents 57 cardiac dysfunction 57 mammographically 57 KRAS mutations occur 57 Observational studies 57 lymph node enlargement 57 TMPRSS2 ERG fusion 57 #F FDG 57 CYPHER Stent 57 Randomized clinical trials 57 K ras mutation 57 conventional coronary angiography 57 nomograms 57 thromboembolic events 57 metastatic prostate 57 valvular heart 57 transfusion transmitted 57 FGFR2 gene 57 sentinel lymph nodes 57 curable cancers 57 Stage IIIb 57 transarterial 57 percutaneous intervention 57 multicenter trials 57 prospective multicenter study 57 bile duct cancers 57 neoplastic 57 PNH patients 57 mycophenolate 57 OHR/AVR# 57 transabdominal 57 TT genotype 57 chlamydial 57 Severe Primary IGFD 57 thyroglobulin 57 pentoxifylline 57 HER2 expression 57 astrocytomas 57 intra arterial chemotherapy 57 nonischemic 57 serrated polyps 57 TMP SMX 57 clinically detectable 57 atherothrombotic 57 BRCA1 BRCA2 57 endocrine therapies 57 precancerous cervical 57 fibrosarcoma 57 intraoperative complications 57 Legg Calvé Perthes disease 57 post thrombotic syndrome 57 EGFR mutation status 57 doxorubicin Adriamycin 57 chemoresistant 57 TNF antagonist 57 antiepileptics 57 Rectal cancer 57 upper gastrointestinal bleeding 57 undergoing radical prostatectomy 57 recurrent ischemia 57 Histologically 57 hepatic function 57 breast carcinomas 57 transvaginal sonography 57 Mitral valve repair 57 multivariable analysis 57 histopathological examination 57 newer atypical antipsychotics 57 Rev Dex 57 nonalcoholic steatohepatitis 57 somatostatin analogs 57 etiologic 57 nasopharyngeal carcinoma 57 NATRECOR ® 57 coronary computed tomography 57 biliary tract cancers 57 systemic toxicity 57 pulmonary resection 57 protease inhibitor PI 57 Eisenmenger syndrome 57 SPECT CT imaging 57 polycythemia vera PV 57 valvular heart disease 57 genomic alterations 57 FGFs 57 mycophenolate mofetil 57 Histologic 57 thrombophilia 57 hepatic toxicity 57 patients undergoing CABG 57 DVT prophylaxis 57 anti androgens 57 CMV infection 57 dysplastic lesions 57 T1c 57 mediastinum 57 nodular melanoma 57 bioprosthetic valve 57 immunochemical 57 lobular carcinoma 57 carotid bruit 57 dosage regimens 57 BR.# 57 thalidomide Thalomid 57 enzastaurin 57 colorectal polyp 57 immunosuppressive agents 57 MDCT angiography 57 FDG PET CT 57 allogeneic transplant 57 survivin expression 57 antiphospholipid antibodies 57 transthoracic 57 benign moles 57 carotid angioplasty 57 diverticular bleeding 57 Liver biopsy 57 neoplasia 57 BRCA deficient 57 external beam radiotherapy 57 recurrent bladder 57 gross hematuria 57 CMV disease 57 Adverse effects 57 clinicopathological features 57 Sjögren syndrome 57 taxane resistant 57 surgical resection cavity 57 sleeve lobectomy 57 aromatase inhibitor therapy 57 ICSs 57 chemotherapy cisplatin 57 duodenal 57 proliferative diabetic retinopathy 57 leukoreduction 57 benign neoplasms 57 LHRH agonists 57 multivessel coronary artery 57 renal cortical 57 vascular insufficiency 57 CSF biomarkers 57 Acute myeloid leukemia 57 paclitaxel eluting stents 57 normal karyotype 57 myeloablative 57 thyroid nodule 57 pre malignant lesions 57 EGFR inhibitors 57 EXJADE 57 Polycythemia vera 57 logistic regression analysis 57 choroidal neovascularization 57 randomized controlled trials RCTs 56 cytologically 56 endometrial cancers 56 fibrate drugs 56 intravenous diuretics